Search over 3,000 reports

    Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast - 2025

    Pulmonary Arterial Hypertension (PAH)  - Market Insights, Epidemiology and Market Forecast - 2025
    Date: Aug, 2017
    Type: Pharmaceutical Industry Report
    Pages: 70
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DIMI0017
    DelveInsight's "Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Pulmonary Arterial Hypertension (PAH) for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Pulmonary Arterial Hypertension (PAH) . It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Pulmonary Arterial Hypertension (PAH) for 7 major markets.

    The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the Report highlights the frontrunners, the drivers and barriers for the Pulmonary Arterial Hypertension (PAH) market, as well as treatment algorithm, current treatments & advancements are included. The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Pulmonary Arterial Hypertension (PAH) , providing an in-depth analysis of emerging therapies which will create an impact through their launch.

    According to DelveInsight, the forecasted patient population of Pulmonary Arterial Hypertension (PAH) for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Pulmonary Arterial Hypertension (PAH) 7MM market size is estimated to be USD XX by 2025. The DelveInsight Report will help in enhanced understanding of the Pulmonary Arterial Hypertension (PAH) market from inside out, with transparency into the calculated patient forecasting data and estimated market size.

    Key Coverage

    • Understanding historical and forecasted epidemiological data for Pulmonary Arterial Hypertension (PAH) covering 7MM from 2015-2025.
    • Segment level epidemiology and market split for Pulmonary Arterial Hypertension (PAH) .
    • The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Pulmonary Arterial Hypertension (PAH) .
    • The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Pulmonary Arterial Hypertension (PAH) market trends.
    • Thorough market distribution based on market share for Pulmonary Arterial Hypertension (PAH) .

    Reasons to buy

    • The report will help in developing business strategies by understanding trends shaping and driving the Pulmonary Arterial Hypertension (PAH) market.
    • To understand the future market competition in the Pulmonary Arterial Hypertension (PAH) market and Insightful review of the key market drivers and barriers.
    • Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension (PAH) in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
    • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
    1. Report Introduction
    2. Pulmonary Arterial Hypertension (PAH) Market Overview at a Glance
    2.1. Total Market Share Distribution of Pulmonary Arterial Hypertension (PAH) for 7 MM in 2016
    2.2. Total Market Share Distribution of Pulmonary Arterial Hypertension (PAH) for 7 MM in 2025
    3. Pulmonary Arterial Hypertension (PAH)
    3.1.1. Overview
    3.1.2. Symptoms
    3.1.3. Pathophysiology
    3.1.4. Staging
    3.1.5. Diagnosis
    3.1.6. Treatment
    4. Epidemiology and Patient Population
    4.1.1. United States
    4.1.1.1. Diagnosed Cases of Pulmonary Arterial Hypertension (PAH) in United States
    4.1.2. Germany
    4.1.2.1. Diagnosed Cases of Pulmonary Arterial Hypertension (PAH) in Germany
    4.1.3. France
    4.1.3.1. Diagnosed Cases of Pulmonary Arterial Hypertension (PAH) in France
    4.1.4. Italy
    4.1.4.1. Diagnosed Cases of Pulmonary Arterial Hypertension (PAH) in Italy
    4.1.5. Spain
    4.1.5.1. Diagnosed Cases of Pulmonary Arterial Hypertension (PAH) in Spain
    4.1.6. United Kingdom
    4.1.6.1. Diagnosed Cases of Pulmonary Arterial Hypertension (PAH) in United Kingdom
    5. Treatment Algorithm
    5.1.1. Treatment Guidelines/Practices
    6. Marketed Drugs for Pulmonary Arterial Hypertension (PAH)
    6.1. Drug 1: Company A
    6.1.1. Drug Description
    6.1.2. Mechanism of Action
    6.1.3. Regulatory Milestones
    6.1.4. Advantages & Disadvantages
    6.1.5. Safety and Efficacy
    6.1.6. Product Profile
    6.1.7. Patent Status
    6.2. Drug 2: Company B
    6.2.1. Drug Description
    6.2.2. Mechanism of Action
    6.2.3. Regulatory Milestones
    6.2.4. Advantages & Disadvantages
    6.2.5. Safety and Efficacy
    6.2.6. Product Profile
    6.2.7. Patent Status
    7. Emerging Therapies
    7.1. Drug 3: Company C
    7.1.1. Description
    7.1.2. Regulatory Milestones
    7.1.3. Advantages & Disadvantages
    7.1.4. Product Profile
    7.1.5. Launch Date
    7.1.6. Clinical Development
    7.1.7. Clinical Pipeline Activity
    7.1.8. Ongoing Trials Information
    7.1.9. Clinical Trial by Phase
    7.2. Drug 4: Company B
    7.2.1. Description
    7.2.2. Regulatory Milestones
    7.2.3. Advantages & Disadvantages
    7.2.4. Product Profile
    7.2.5. Launch Date
    7.2.6. Clinical Development
    7.2.7. Clinical Pipeline Activity
    7.2.8. Ongoing Trials Information
    7.2.9. Clinical Trial by Phase
    8. Overview of Total Pulmonary Arterial Hypertension (PAH) Market (2016 & 2025)
    9. Pulmonary Arterial Hypertension (PAH) : Country-Wise Market Analysis
    9.1. United States
    9.1.1. Historical Market Size (2015-2016)
    9.1.2. Forecasted Market Size (2017-2025)
    9.2. Germany Market Size
    9.2.1. Historical Market Size (2015-2016)
    9.2.2. Forecasted Market Size (2017-2025)
    9.3. France Market Size
    9.3.1. Historical Market Size (2015-2016)
    9.3.2. Forecasted Market Size (2017-2025)
    9.4. United Kingdom Market Size
    9.4.1. Historical Market Size (2015-2016)
    9.4.2. Forecasted Market Size (2017-2025)
    9.5. Spain Market Size
    9.5.1. Historical Market Size (2015-2016)
    9.5.2. Forecasted Market Size (2017-2025)
    9.6. Italy Market Size
    9.6.1. Historical Market Size (2015-2016)
    9.6.2. Forecasted Market Size (2017-2025)
    9.7. Japan Market Size
    9.7.1. Historical Market Size (2015-2016)
    9.7.2. Forecasted Market Size (2017-2025)
    10. Market Drivers
    11. Market Restraints
    12. Appendix
    13. Report Methodology
    14. Consulting Services
    15. Disclaimer
    16. About DelveInsight
    Table 1: Diagnosed Cases Pulmonary Arterial Hypertension (PAH) in United States (2015-2025)
    Table 2: Diagnosed Cases Pulmonary Arterial Hypertension (PAH) in Germany (2015-2025)
    Table 3: Diagnosed Cases Pulmonary Arterial Hypertension (PAH) in France (2015-2025)
    Table 4: Diagnosed Cases Pulmonary Arterial Hypertension (PAH) in United Kingdom (2015-2025)
    Table 5: Diagnosed Cases Pulmonary Arterial Hypertension (PAH) in Spain (2015-2025)
    Table 6: Diagnosed Cases Pulmonary Arterial Hypertension (PAH) in Italy (2015-2025)
    Table 7: Diagnosed Cases Pulmonary Arterial Hypertension (PAH) in Japan (2015-2025)
    Table 8: List of Marketed Drugs for Pulmonary Arterial Hypertension (PAH)
    Table 9: List of Pipeline Phase III Drugs for Pulmonary Arterial Hypertension (PAH)
    Table 10: Drug 1, Clinical Trials by Zone, 2017
    Table 11: Clinical Trials by Trial status, 2017
    Table 12: Drug 2, Clinical Trials by Zone, 2017
    Table 13: Clinical Trials by Trial status, 2017
    Table 14: Drug 3, Clinical Trials by Zone, 2017
    Table 15: Clinical Trials by Trial status, 2017
    Table 16: United States Market Size of Pulmonary Arterial Hypertension (PAH) in USD, Million (2015-2025)
    Table 17: Germany Market Size of Pulmonary Arterial Hypertension (PAH) in USD, Million (2015-2025)
    Table 18: France Market Size of Pulmonary Arterial Hypertension (PAH) in USD, Million (2015-2025)
    Table 19: United Kingdom Market Size of Pulmonary Arterial Hypertension (PAH) in USD, Million (2015-2025)
    Table 20: Spain Market Size of Pulmonary Arterial Hypertension (PAH) in USD, Million (2015-2025)
    Table 21: Italy Market Size of Pulmonary Arterial Hypertension (PAH) in USD, Million (2015-2025)
    Table 22: Japan Market Size of Pulmonary Arterial Hypertension (PAH) in USD, Million (2015-2025)

    Figure 1: Diagnosed Cases Pulmonary Arterial Hypertension (PAH) in United States (2015-2025)
    Figure 2: Diagnosed Cases Pulmonary Arterial Hypertension (PAH) in Germany (2015-2025)
    Figure 3: Diagnosed Cases Pulmonary Arterial Hypertension (PAH) in France (2015-2025)
    Figure 4: Diagnosed Cases Pulmonary Arterial Hypertension (PAH) in United Kingdom (2015-2025)
    Figure 5: Diagnosed Cases Pulmonary Arterial Hypertension (PAH) in Spain (2015-2025)
    Figure 6: Diagnosed Cases Pulmonary Arterial Hypertension (PAH) in Italy (2015-2025)
    Figure 7: Diagnosed Cases Pulmonary Arterial Hypertension (PAH) in Japan (2015-2025)
    Figure 8: List of Marketed Drugs for Pulmonary Arterial Hypertension (PAH)
    Figure 9: List of Pipeline Phase III Drugs for Pulmonary Arterial Hypertension (PAH)
    Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
    Figure 11: Clinical Trials by Trial status, 2017
    Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
    Figure 13: Clinical Trials by Trial status, 2017
    Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
    Figure 15: Clinical Trials by Trial status, 2017
    Figure 16: United States Market Size of Pulmonary Arterial Hypertension (PAH) in USD, Million (2015-2025)
    Figure 17: Germany Market Size of Pulmonary Arterial Hypertension (PAH) in USD, Million (2015-2025)
    Figure 18: France Market Size of Pulmonary Arterial Hypertension (PAH) in USD, Million (2015-2025)
    Figure 19: United Kingdom Market Size of Pulmonary Arterial Hypertension (PAH) in USD, Million (2015-2025)
    Figure 20: Spain Market Size of Pulmonary Arterial Hypertension (PAH) in USD, Million (2015-2025)
    Figure 21: Italy Market Size of Pulmonary Arterial Hypertension (PAH) in USD, Million (2015-2025)
    Figure 22: Japan Market Size of Pulmonary Arterial Hypertension (PAH) in USD, Million (2015-2025)

    Pulmonary Arterial Hypertension (PAH) Market (7MM)

    Pulmonary Arterial Hypertension (PAH) Market forecasting

    Pulmonary Arterial Hypertension (PAH) Sales forecasting

    Pulmonary Arterial Hypertension (PAH) Market segments

    Pulmonary Arterial Hypertension (PAH) Epidemiology

    Pulmonary Arterial Hypertension (PAH) Pipeline products and technologies

    Pulmonary Arterial Hypertension (PAH) Competitive landscape

    Pulmonary Arterial Hypertension (PAH) SWOT analysis

    Pulmonary Arterial Hypertension (PAH) Market Driver's and barriers

    Pulmonary Arterial Hypertension (PAH) Key Companies and Funding

    • Single User License
      $5,750.00
    • Site License
      $11,500.00
    • Global License
      $17,250.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap